Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT04270461 |
| NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors |
| withdrawn |
| Phase 1 |
| 0 |
| Jiujiang University Affiliated HospitalOTHER_GOV |
| 1 |
| Oct 22, 2020 |
| clinicaltrials |
| NCT01916187 | Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma | withdrawn | Phase 1 | 0 | NCIC Clinical Trials GroupNETWORK | 1 | Sep 21, 2020 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT04388033 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | unknown | Phase 1 / Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 0 | May 20, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00011414 | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | terminated | Phase 1 / Phase 2 | 24 | Centre Leon BerardOTHER | 4 | May 21, 2019 | clinicaltrials |
| NCT01313936 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | completed | Phase 1 | 32 | University of California, San FranciscoOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03416517 | Anlotinib and Irinotecan for Ewing Sarcoma | unknown | Phase 1 / Phase 2 | 47 | Peking University People's HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02173093 | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | unknown | Phase 1 / Phase 2 | 40 | University of VirginiaOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02337309 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 1 | 4 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01462396 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors(STALLO) | completed | Phase 1 | 4 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01610570 | Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | terminated | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2018 | clinicaltrials |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01171469 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | completed | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2020source: clinicaltrials